Get Involved

What is the purpose of this study?

The aim of the MARS2 study is to determine if it is feasible to enrol patients with mesothelioma into a study randomising them to chemotherapy only or chemotherapy and lung-sparing surgery. Patients will be followed up regularly at their usual clinic visits for up to 5 years. Patients will be asked to complete a Quality of Life Questionnaire at these visits. Tissue samples will be taken at the time of diagnosis and at surgery (if they are randomised to surgery) for mesothelioma research central storage and blood samples will be taken at the clinic visits up to 12 months for mesothelioma research central storage. If we can show the feasibility of recruitment we will apply to continue the study to include more patients in order to determine if lung-sparing surgery improves survival and quality of life for mesothelioma patients.

 

To find out more please visit the MARS2 website or contact:

Judith Moore, Clinical Trials Officer (0191) 404 1000 Ex 2263

Customer Services, (0191) 404 1072

Clinical Trials in Respiratory Disorders

Select a trial from the list below to find out more about what it’s all about and how you can get involved in helping others.

EMBARC – The European Bronchiectasis Registry

This study is seeking to establish a register of patients diagnosed with bronchiectasis around Europe.

EME – TIPAC – Idiopathic Pulmonary Fibrosis Study

Treating pulmonary fibrosis with co-trimoxazole

LuCID Lung Cancer Indicator Detection

The goal of this study is to carefully look at the compounds someone exhales to determine if analysis of exhaled breath can detect lung cancer.

NIVO – 1 year longitudinal follow up after assisted ventilation

This study aims to track the progress of patients that have required assisted ventilation for one year after discharge from hospital.

Instage-IPF IMP study

This study is for patients that have been diagnosed with Idiopathic pulmonary fibrosis.

MARS2

The aim of the MARS2 study is to determine if it is feasible to enrol patients with mesothelioma into a study randomising them to chemotherapy only or chemotherapy and lung-sparing surgery.


Latest news from PPI

View all